On May 18, 2026, the U.S. Supreme Court declined to review a Medicaid award case involving Eli Lilly. This denial upholds the lower court's judgment against the company.
The ruling solidifies Eli Lilly's Medicaid-related financial obligations. The decision removes legal uncertainty regarding operational strategies for Medicaid-related revenues.